190 related articles for article (PubMed ID: 19967781)
21. An evaluation of salt screening methodologies.
Fernández Casares A; Nap WM; Ten Figás G; Huizenga P; Groot R; Hoffmann M
J Pharm Pharmacol; 2015 Jun; 67(6):812-22. PubMed ID: 25683791
[TBL] [Abstract][Full Text] [Related]
22. Preformulation investigation and challenges; salt formation, salt disproportionation and hepatic recirculation.
Sigfridsson K; Nilsson L; Ahlqvist M; Andersson T; Granath AK
Eur J Pharm Sci; 2017 Jun; 104():262-272. PubMed ID: 28366653
[TBL] [Abstract][Full Text] [Related]
23. Measurement and Accurate Interpretation of the Solubility of Pharmaceutical Salts.
He Y; Ho C; Yang D; Chen J; Orton E
J Pharm Sci; 2017 May; 106(5):1190-1196. PubMed ID: 28153596
[TBL] [Abstract][Full Text] [Related]
24. Effect of counterions on the properties of amorphous atorvastatin salts.
Sonje VM; Kumar L; Puri V; Kohli G; Kaushal AM; Bansal AK
Eur J Pharm Sci; 2011 Nov; 44(4):462-70. PubMed ID: 21907794
[TBL] [Abstract][Full Text] [Related]
25. Solubility of lysozyme in the presence of aqueous chloride salts: common-ion effect and its role on solubility and crystal thermodynamics.
Annunziata O; Payne A; Wang Y
J Am Chem Soc; 2008 Oct; 130(40):13347-52. PubMed ID: 18788805
[TBL] [Abstract][Full Text] [Related]
26. Effect of counterions on physicochemical properties of prazosin salts.
Kumar L; Meena CL; Pawar YB; Wahlang B; Tikoo K; Jain R; Bansal AK
AAPS PharmSciTech; 2013 Mar; 14(1):141-50. PubMed ID: 23250707
[TBL] [Abstract][Full Text] [Related]
27. The influence of aqueous content in small scale salt screening--improving hit rate for weakly basic, low solubility drugs.
Tarsa PB; Towler CS; Woollam G; Berghausen J
Eur J Pharm Sci; 2010 Sep; 41(1):23-30. PubMed ID: 20553863
[TBL] [Abstract][Full Text] [Related]
28. Preformulation investigation of some clopidogrel addition salts.
Zupančič V; Smrkolj M; Benkič P; Simonič I; Plevnik M; Ritlop G; Kristl A; Vrečer F
Acta Chim Slov; 2010 Jun; 57(2):376-85. PubMed ID: 24061734
[TBL] [Abstract][Full Text] [Related]
29. Physical stability of salts of weak bases in the solid-state.
Stephenson GA; Aburub A; Woods TA
J Pharm Sci; 2011 May; 100(5):1607-17. PubMed ID: 21374599
[TBL] [Abstract][Full Text] [Related]
30. Comparative physical, mechanical and crystallographic properties of a series of gemfibrozil salts.
David SE; Ramirez M; Timmins P; Conway BR
J Pharm Pharmacol; 2010 Nov; 62(11):1519-25. PubMed ID: 21039537
[TBL] [Abstract][Full Text] [Related]
31. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
Elder DP; Holm R; Diego HL
Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
[TBL] [Abstract][Full Text] [Related]
32. Preparation and characterization of new salts of tioconazole. Comparison of their dissolution performance.
Moroni AB; Mayoral EP; Lionello DF; Vega DR; Kaufman TS; Calvo NL
Int J Pharm; 2024 Mar; 652():123855. PubMed ID: 38280497
[TBL] [Abstract][Full Text] [Related]
33. Role of salt and excipient properties on disproportionation in the solid-state.
Guerrieri P; Taylor LS
Pharm Res; 2009 Aug; 26(8):2015-26. PubMed ID: 19507008
[TBL] [Abstract][Full Text] [Related]
34. Disproportionation of Pharmaceutical Salts: pH
Avdeef A
Mol Pharm; 2021 Jul; 18(7):2724-2743. PubMed ID: 34142831
[TBL] [Abstract][Full Text] [Related]
35. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes.
Ruan LP; Yu BY; Fu GM; Zhu DN
J Pharm Biomed Anal; 2005 Jul; 38(3):457-64. PubMed ID: 15925247
[TBL] [Abstract][Full Text] [Related]
36. Preparation and characterisation of hexamidine salts.
Parisi N; Matts PJ; Lever R; Hadgraft J; Lane ME
Int J Pharm; 2015 Sep; 493(1-2):404-11. PubMed ID: 26235920
[TBL] [Abstract][Full Text] [Related]
37. Diflunisal salts of bupivacaine, lidocaine and morphine. Use of the common ion effect for prolonging the release of bupivacaine from mixed salt suspensions in an in vitro dialysis model.
Larsen SW; Østergaard J; Poulsen SV; Schulz B; Larsen C
Eur J Pharm Sci; 2007 Jul; 31(3-4):172-9. PubMed ID: 17462869
[TBL] [Abstract][Full Text] [Related]
38. Estimating the maximal solubility advantage of drug salts.
Skrdla PJ
Int J Pharm; 2021 Feb; 595():120228. PubMed ID: 33484924
[TBL] [Abstract][Full Text] [Related]
39. Temperature invariance of NaCl solubility in water: inferences from salt-water cluster behavior of NaCl, KCl, and NH4Cl.
Bharmoria P; Gupta H; Mohandas VP; Ghosh PK; Kumar A
J Phys Chem B; 2012 Sep; 116(38):11712-9. PubMed ID: 22937984
[TBL] [Abstract][Full Text] [Related]
40. Structure, solubility, screening, and synthesis of molecular salts.
Black SN; Collier EA; Davey RJ; Roberts RJ
J Pharm Sci; 2007 May; 96(5):1053-68. PubMed ID: 17455329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
